若生智能
Drug Database
DI

didanosine (didanosine EC / Videx EC)

✓ Approved

Bristol-Myers Squibb · · 小分子

什么是 didanosine？

didanosine 是一种小分子，由Bristol-Myers Squibb研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名didanosine EC, Videx EC
公司Bristol-Myers Squibb
药物类别小分子
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Bristol-Myers Squibb

作用机制

分子靶点

didanosine 作用于 1 个分子靶点：

gag-pol, HIV-1 (gag-pol)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

didanosine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsAcquired immunodeficiency syndrome✓ Approved

相关研究文献

PubMedVeterinary ophthalmology2026-08-04

Effects of Topical Omidenepag Isopropyl on Intraocular Pressure and Pupil Diameter in Normal Dogs.

Tsujimura Hikaru H, Kameda Tomoaki T, Oikawa Kazuya K, Takahashi Hiroki H

To determine the effects of 0.002% omidenepag isopropyl (OMDI) ophthalmic solution on intraocular pressure (IOP) and pupil diameter (PD) in clinically normal dogs. Five healthy dogs (10 eyes) were included in this prospective randomized, observer-masked, placebo-controlled study. An initial pilot study was conducted to evaluate IOP and ocular irritation up to 48 h after a single instillation of OMDI. For the subsequent main study, each dog received one drop of 0.002% OMDI in one randomly selected eye and placebo in the contralateral eye once daily. IOP, PD, and conjunctival hyperemia scores were measured five times daily during the baseline (3 days), treatment (5 days), and recovery (3 days) periods. A single instillation of topical OMDI significantly lowered IOP by a maximal IOP reduction of 7.2 mmHg (60%). In the repeated-dose study, once-daily administration of topical OMDI significantly reduced average daily IOP ± SD by 4.8 ± 0.68 mmHg (38.6%) and 6.1 ± 0.75 mmHg (44.3%), relative to baseline and contralateral controls, respectively. No clinically relevant miosis was observed in OMDI-treated eyes. Adverse events were limited to mild-to-moderate conjunctival hyperemia in OMDI-treated eyes. Once-daily administration of 0.002% OMDI resulted in a robust reduction in IOP without inducing miosis and was well-tolerated in normal dogs. Further studies are warranted to assess its therapeutic potential and long-term safety in dogs with glaucoma.

PMID 42549739
阅读全文 →
PubMedBone & joint research2026-08-04

A target-based population pharmacokinetic and pharmacodynamic analysis for intra-articular dosing regimen optimization of vancomycin in patients with periprosthetic joint infections.

Liu Wenyuan W, Wang Wei-Jun WJ, Ding Manzhen M, Zhang Minghao M et al.

Although intra-articular vancomycin has demonstrated satisfactory outcomes for periprosthetic joint infection (PJI), dose and dosing frequency remain largely empirical. This study aimed to develop a target-based population pharmacokinetics (PK) model to predict local vancomycin exposure, and to evaluate the efficacy and safety of various regimens in patients with PJI. Patients with PJI who received intravenous (IV) infusion or intra-articular injection of vancomycin were included. Population PK analysis was performed using nonlinear mixed effects modelling. Monte Carlo simulations were used to assess pharmacodynamic target attainment against Staphylococcus species, and to evaluate vancomycin-associated safety risks. A total of 450 plasma and synovial fluid samples from 161 patients with PJI were analyzed. The pharmacokinetics of vancomycin in synovial fluid were best described by a two-compartment joint model linked to a central plasma compartment. Creatinine clearancesignificantly affected systemic clearance, while age influenced the penetration from synovial fluid to the central compartment. Simulations suggested that intra-articular dosing of 500 mg once daily was sufficient for targets against Staphylococcus aureus and Staphylococcus epidermidis, whereas other coagulase-negative staphylococci required more intensive regimens, including 250 or 500 mg every 12 hours or 1,000 mg once daily. For patients with severe renal impairment, intra-articular administration alone provided adequate systemic exposure, and concomitant IV administration was not recommended. The intra-articular population PK model accurately characterized vancomycin concentrations in plasma and synovial fluid, supporting optimized intra-articular dosing regimens in patients with PJI according to renal function and age.

PMID 42547054
阅读全文 →
PubMedAnnals of dermatology2026-08-04

A Multi-Center, Open-Label, Single-Arm, Prospective Investigator Initiated Trial to Evaluate the Efficacy and Safety of Alitretinoin in Patients With Chronic Hand Eczema in Real-World Practice (DWALG_P401) and Overview of Korean Studies.

Kwon Min Jung MJ, Yu Jin Woo JW, Han Byeol B, Ahn Jiyoung J et al.

Chronic hand eczema (CHE) is a debilitating dermatologic condition often refractory to topical corticosteroids (TCS). Although oral alitretinoin has demonstrated efficacy in CHE, real-world multicenter data in Korean populations remain limited. To evaluate the real-world efficacy and safety of oral alitretinoin in Korean patients with severe CHE with insufficient response to TCS. This multicenter, prospective, open-label study enrolled 146 patients with severe CHE at tertiary hospitals in Korea. Patients received oral alitretinoin (30 mg once daily, with dose reduction to 10 mg permitted) for up to 24 weeks, with observation up to 36 weeks. The primary endpoint was achievement of "clear" or "almost clear" on the Physician's Global Assessment (PGA) at treatment completion. Secondary endpoints included the modified total lesion symptom score (mTLSS) and Patient's Global Assessment (PaGA). Safety was evaluated by monitoring adverse events (AEs) and laboratory abnormalities. Efficacy analyses were performed on the full analysis set (n=129). At treatment completion, 55 patients (42.64%) achieved a PGA response. Improvement increased from week 4 (1.83%) to week 36 (60.87%). PaGA showed consistent improvement, with 17.32% reporting "clear or almost clear" and 28.35% reporting "marked improvement" at treatment completion. mTLSS scores improved by 62.3% at treatment completion and by 75.7% at week 36. In the safety analysis (n=134), 44.03% experienced AEs, most commonly headache (29.10%). Oral alitretinoin at daily doses of 10 mg or 30 mg demonstrated effective symptom improvement and an acceptable safety profile in Korean patients with CHE in a real-world setting.

PMID 42547475
阅读全文 →
PubMedFrontiers in psychiatry2026-08-04

Integrating cognitive-behavioral training with immersive virtual reality intervention in ADHD: a case report.

Settimo Carmela C, Cantale Aeo Doriana D, Lombardo Facciale Antonino A, Turriziani Laura L et al.

Attention-Deficit/Hyperactivity Disorder (ADHD) is a condition characterized by persistent patterns of inattention and/or hyperactivity-impulsivity. This case highlights the potential benefit of integrating Immersive Virtual Reality (IVR) with cognitive-behavioral therapy (CBT) in the rehabilitation of a child with ADHD. It contributes to emerging evidence by showing how a combined approach may simultaneously target executive, attentional, and motor domains within a single intervention. An 8-year-old child with deficits in sustained and selective attention, impaired executive functioning (including planning and working memory), impulsivity, and difficulties in motor regulation, as revealed during baseline assessments, impacting daily functioning. The patient was diagnosed with combined-type ADHD and underwent a 12-week CBT intervention, followed by integrated IVR-CBT intervention targeting executive functions and self-control, once a week for 12 weeks. The intervention was conducted using the CAREN (Computer Assisted Rehabilitation Environment), an immersive virtual reality platform integrating multisensory input and interactive tasks to promote cognitive and motor engagement. Post-intervention assessments showed improvements in sustained and selective attention, planning, working memory, and balance. There was also an increase in involvement and a reduction in impulsivity. The findings support the hypothesis that immersive, embodied interventions targeting both executive and sensorimotor processes may represent a promising novelty adjunctive rehabilitation approach. Further studies are needed to evaluate efficacy, generalizability, and to confirm these findings in larger samples. This case report was prepared in accordance with the CARE Guidelines.

PMID 42548748
阅读全文 →
PubMedJournal of the National Cancer Institute2026-08-04

Electroacupuncture for acute gastrointestinal symptoms during chemotherapy for colorectal cancer: a randomized clinical trial.

Chen Ziwen Z, Xu Tao T, Sun Mingsheng M, Li Qifu Q et al.

Acute chemotherapy-related gastrointestinal symptoms can limit colorectal cancer treatment. We evaluated electroacupuncture as adjunctive care for acute gastrointestinal symptom burden during chemotherapy. This multicenter, randomized, patient- and assessor-blinded, sham-controlled trial was conducted at 6 tertiary hospitals in China from July 2022 to August 2025. Adults with colorectal cancer and chemotherapy-related gastrointestinal symptoms were randomly assigned 1 1:1 to electroacupuncture, nonpenetrating sham acupuncture, or usual care. Treatments were given once daily for 3 days during chemotherapy. The primary outcome was change in Gastrointestinal Symptom Rating Scale (GSRS) total score from baseline to day 3. Secondary outcomes included rescue medication use and adverse events. Among 230 randomized patients (mean age, 60.1 years; 54.3% men), 211 (91.7%) completed the 3-day intervention. At day 3, electroacupuncture reduced GSRS total scores more than sham acupuncture (mean difference [MD], -1.54; 95% CI, -2.35 to -0.74; P < .001) and usual care (MD, -1.30; 95% CI, -2.09 to -0.50; P = .001). These differences did not exceed the prespecified minimal clinically important difference of 2.15 points. Electroacupuncture was associated with higher odds of remaining rescue-free than sham acupuncture (adjusted OR, 2.86; 95% CI, 1.23 to 6.63; P = .015) and usual care (adjusted OR, 2.64; 95% CI, 1.16 to 6.01; P = .021). No serious adverse events occurred. Electroacupuncture was associated with statistically significant but modest short-term reductions in acute gastrointestinal symptom burden. The between-group differences did not exceed the prespecified clinical-importance threshold and should be interpreted cautiously. Chinese Clinical Trials Register identifier ChiCTR2200062317.

PMID 42550476
阅读全文 →
PubMedCurrent biology : CB2026-08-04

Microbial metabolism: Reactivating the molecular motor of the biological methane generator.

Wagner Tristan T

The methane-generating enzyme from methanogenic archaea must be reactivated via a dedicated system. New molecular insights demonstrate that a key component of the reactivation machinery is redox sensitive, binds the methane-forming enzyme via an ATP-dependent switch, and hydrolyses ATP once bound.

PMID 42546678
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多didanosine